Research
Print page Print page
Switch language
Rigshospitalet - a part of Copenhagen University Hospital
Published

Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial

Research output: Contribution to journalJournal articleResearchpeer-review

DOI

  1. Risk of over- And under- treatment with levothyroxine in primary care in Copenhagen, Denmark

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Risk factors for hyperglycemia in pregnancy in the DALI study differ by period of pregnancy and OGTT time point

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. THERAPY OF ENDOCRINE DISEASE: Growth hormone replacement therapy in adults: 30 years of personal clinical experience

    Research output: Contribution to journalReviewResearchpeer-review

  4. Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. SGLT2 inhibitors: Clinical benefits by restoration of normal diurnal metabolism?

    Research output: Contribution to journalReviewResearchpeer-review

  • Leo Niskanen
  • Lawrence A Leiter
  • Edward Franek
  • Jianping Weng
  • Taner Damci
  • Manuel Muñoz-Torres
  • Jean-Paul Donnet
  • Lars Endahl
  • Trine Vang Skjøth
  • Allan Vaag
View graph of relations
Insulin degludec/insulin aspart (IDegAsp) is a soluble co-formulation of insulin degludec (70%) and insulin aspart (IAsp: 30%). Here, we compare the efficacy and safety of IDegAsp, an alternative IDegAsp formulation (AF: containing 45% IAsp), and biphasic IAsp 30 (BIAsp 30).
Original languageEnglish
JournalEuropean Journal of Endocrinology
Volume167
Issue number2
Pages (from-to)287-94
Number of pages8
ISSN0804-4643
DOIs
Publication statusPublished - 2012

    Research areas

  • Adolescent, Adult, Aged, Biphasic Insulins, Chemistry, Pharmaceutical, Diabetes Mellitus, Type 2, Drug Administration Schedule, Drug Combinations, Female, Hemoglobin A, Glycosylated, Humans, Hypoglycemic Agents, Insulin Aspart, Insulin, Isophane, Insulin, Long-Acting, Male, Metformin, Middle Aged, Solubility, Treatment Outcome, Young Adult

ID: 36878777